Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...

Also Read: RJK Jr.’s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing At an interim analysis, the Keytruda plus Lenvima-based regimen demonstrated a statistically significant ...

Merck’s top-line growth in the fourth quarter is likely to have been driven by cancer drug Keytruda, like in the previous quarters, backed by additional indications and patient demand.